Catalog No.
DHC09608
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration
0.57 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04626 & P07766
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, Musmus G2a kappa, anti-ERBB2 (250A/TP-A-02) / Rat sp. G2b lambda, anti-CD3E (26/II/6-1.2), TPBs03, CAS: 509077-99-0
Clone ID
Ertumaxomab
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer., PMID:16707606
Gateways to clinical trials., PMID:17235418
ErbB-directed immunotherapy: antibodies in current practice and promising new agents., PMID:18201769
Ertumaxomab: a trifunctional antibody for breast cancer treatment., PMID:18808314
Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis., PMID:19216794
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine., PMID:19346299
The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2., PMID:19435924
Evolving novel anti-HER2 strategies., PMID:19959074
Structural and functional characterization of the trifunctional antibody catumaxomab., PMID:20418662
Targeted therapy in breast cancer: what's new?, PMID:21706452
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment., PMID:22126733
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling., PMID:22820509
Targeting the HER2 receptor in metastatic breast cancer., PMID:23095788
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors., PMID:27387446
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment., PMID:29209558
Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment., PMID:37519200
Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis, PMID: 19216794
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment, PMID: 22126733
Structural and functional characterization of the trifunctional antibody catumaxomab, PMID: 20418662
Targeting the HER2 receptor in metastatic breast cancer, PMID: 23095788
ErbB-directed immunotherapy: antibodies in current practice and promising new agents, PMID: 18201769
Evolving novel anti-HER2 strategies, PMID: 19959074
Gateways to clinical trials, PMID: 17235418
Targeted therapy in breast cancer: what's new?, PMID: 21706452
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment, PMID: 29209558
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer, PMID: 16707606
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors, PMID: 27387446
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine, PMID: 19346299
The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2, PMID: 19435924
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling, PMID: 22820509
Ertumaxomab: a trifunctional antibody for breast cancer treatment, PMID: 18808314
For research use only. Not for human or drug use.
